The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Investigating the genomic drivers of resistance to CD19 CAR-T therapy in DLBCL
Chimeric antigen receptor T-cell (CAR-T) therapy has marked a paradigm shift in the treatment of diffuse large B-cell lymphoma (DLBCL). However, half of patients treated with CAR-T therapy eventually relapse. Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the importance of understanding the mechanisms of resistance to CD19 chimeric antigen CAR-T therapy, outlining the results of a study using whole-genome sequencing (WGS) to investigate the genomic drivers involved in DLBCL resistance to CAR-T therapy. The study found that the presence of APOBEC and certain gene deletions were indicative of a poor outcome. Moving forward, Dr Maura explains that it is essential to improve our understanding of the interplay between CAR-Ts, cancer cells and the immune system to develop CAR-T therapies that are adapted to each patient. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
